Physician profile
Nathan Jones
NPI 1093864480
$960.18
in general payments reported to CMS, 2019-2025
15 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.10 · 2020: $22.01 · 2023: $97.02 · 2024: $21.59 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666 · Travel and Lodging: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.38 |
| Travel and Lodging | $185.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $185.69 | 2025 | Mako |
| Caris Mpi, INC. | $171.50 | 2025 | Mi Cancer Seek |
| Siemens Medical Solutions USA, INC. | $136.33 | 2025 | Varian Ethos Treatment Planning |
| Astrazeneca Pharmaceuticals LP | $107.53 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $97.02 | 2023 | Pylarify |
| Carl Zeiss Meditec, INC. | $55.73 | 2019 | |
| Pfizer INC. | $38.37 | 2025 | |
| Myriad Genetic Laboratories, INC. | $30.75 | 2025 | Prolaris |
| Sumitomo Pharma America, INC. | $28.98 | 2025 | Orgovyx |
| Foundation Medicine, INC. | $22.01 | 2020 | |
| Agios Pharmaceuticals, INC. | $21.59 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.99 | 2025 | |
| Adaptive Biotechnologies Corporation | $16.32 | 2025 | Clonoseq |
| Tesaro, INC. | $16.11 | 2019 | |
| Merck Sharp & Dohme LLC | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.